Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Approved for marketing 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 27Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Follicular 8Neoplasm Metastasis 5Ovarian Neoplasms 4Neoplasms 3Multiple Myeloma 3Metastatic Castration-resistant Prostate Cancer 3Lymphoma, Non-Hodgkin 3Lymphoma 3Lymphoma, B-Cell 2Endometrial Neoplasms 2Breast Neoplasms 2Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Stomatitis 1Stomach Neoplasms 1Recurrence 1Prostate Cancer Metastatic 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peripheral Nervous System Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oral Ulcer 1Myasthenia Gravis 1Metastatic Castration-Resistant Prostate Cancer Patients 1Metastatic Castration-Resistant Prostate Cancer 1Hodgkin Disease 1Dendritic Cell Sarcoma, Interdigitating 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Abiraterone Acetate 6olaparib 5Prednisone 5enzalutamide 3Prednisolone 3radium Ra 223 dichloride 2Pluvicto 2niraparib 1fludarabine 1darolutamide 1afuresertib 1abiraterone 1Docetaxel 1Cyclophosphamide 1Clinical Trials, Phase I as Topic 1Blood Specimen Collection 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Metastatic Castration-resistant Prostate Cancer × Prednisolone × Clear all
NCT07365995 2026-05-05

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

BioNTech SE

Phase 3 Recruiting
736 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT07553988 2026-04-28

A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer

R-Pharm

Phase 2 Active not recruiting
120 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT05401214 2025-06-13

Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)

Janssen Research & Development, LLC

Approved for marketing
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡